Replication and extension of a model predicting response to psilocybin

被引:44
作者
Russ, Suzanne L. [1 ]
Carhart-Harris, R. L. [2 ]
Maruyama, G. [3 ]
Elliott, M. S. [4 ]
机构
[1] Univ Arizona South, 1140 Columbo Ave, Sierra Vista, AZ 85635 USA
[2] Imperial Coll, London, England
[3] Univ Minnesota, Minneapolis, MN USA
[4] Chicago Publ Sch, Chicago, IL USA
关键词
Psilocybin; Psychedelic; Surrender; Mystical experience; MYSTICAL-TYPE EXPERIENCES; LYSERGIC-ACID DIETHYLAMIDE; CHALLENGING EXPERIENCES; CONSCIOUSNESS; QUESTIONNAIRE; PSYCHEDELICS; VALIDATION; ABSORPTION; GUIDELINES; ATTITUDES;
D O I
10.1007/s00213-019-05279-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Background Recent research demonstrated the potential of psychedelic drugs as treatment for depression and death-related anxiety and as an enhancement for well-being. While generally positive, responses to psychedelic drugs can vary according to traits, setting, and mental state (set) before and during ingestion. Most earlier models explain minimal response variation, primarily related to dosage and trust, but a recent study found that states of surrender and preoccupation at the time of ingestion explained substantial variance in mystical and adverse psilocybin experiences. Objectives The current study sought to replicate the previous model, extend the model with additional predictors, and examine the role of mystical experience on positive change. Method A hierarchical regression model was created with crowdsourced retrospective data from 183 individuals who had self-administered psilocybin in the past year. Scales explored mental states before, during, and after psilocybin ingestion, relying on open-ended memory prompts at each juncture to trigger recollections. Controlled drug administration was not employed. Results This study replicated the previous model, finding a state of surrender before ingestion a key predictor of optimal experience and preoccupation a key predictor of adverse experience. Additional predictors added to the explanatory power for optimal and adverse experience. The model supported the importance of mystical experiences to long-term change. Conclusion Mental states of surrender or preoccupation at the time of ingestion explain variance in mystical or adverse psilocybin experiences, and mystical experiences relate to long-term positive change. The capacity to recognize this optimal preparatory mental state may benefit therapeutic use of psilocybin in clinical settings.
引用
收藏
页码:3221 / 3230
页数:10
相关论文
共 40 条
[1]  
[Anonymous], 2014, DRUG ALCOHOL DEPEND, DOI [10.1016/j.drugalcdep.2014.02.072, DOI 10.1016/J.DRUGALCDEP.2014.02.072, DOI 10.1016/J.DRUGALCDEP]
[2]   Neuroticism is associated with challenging experiences with psilocybin mushrooms [J].
Barrett, Frederick S. ;
Johnson, Matthew W. ;
Griffiths, Roland R. .
PERSONALITY AND INDIVIDUAL DIFFERENCES, 2017, 117 :155-160
[3]   The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms [J].
Barrett, Frederick S. ;
Bradstreet, Matthew P. ;
Leoutsakos, Jeannie-Marie S. ;
Johnson, Matthew W. ;
Griffiths, Roland R. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (12) :1279-1295
[4]   Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin [J].
Barrett, Frederick S. ;
Johnson, Matthew W. ;
Griffiths, Roland R. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2015, 29 (11) :1182-1190
[5]  
Burdzy DC, 2014, SACRED EMOTIONS SCAL
[6]   Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences [J].
Carbonaro, Theresa M. ;
Bradstreet, Matthew P. ;
Barrett, Frederick S. ;
MacLean, Katherine A. ;
Jesse, Robert ;
Johnson, Matthew W. ;
Griffiths, Roland R. .
JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (12) :1268-1278
[7]  
Carhart-Harris R, 2017, COMMUNICATION
[8]   The paradoxical psychological effects of lysergic acid diethylamide (LSD) [J].
Carhart-Harris, R. L. ;
Kaelen, M. ;
Bolstridge, M. ;
Williams, T. M. ;
Williams, L. T. ;
Underwood, R. ;
Feilding, A. ;
Nutt, D. J. .
PSYCHOLOGICAL MEDICINE, 2016, 46 (07) :1379-1390
[9]   Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study [J].
Carhart-Harris, Robin L. ;
Bolstridge, Mark ;
Rucker, James ;
Day, Camilla M. J. ;
Erritzoe, David ;
Kaelen, Mendel ;
Bloomfield, Michael ;
Rickard, James A. ;
Forbes, Ben ;
Feilding, Amanda ;
Taylor, David ;
Pilling, Steve ;
Curran, Valerie H. ;
Nutt, David J. .
LANCET PSYCHIATRY, 2016, 3 (07) :619-627